Overcoming tamoxifen resistance in oestrogen receptor‐positive breast cancer using the novel thiosemicarbazone anti‐cancer agent, DpC
Author:
Affiliation:
1. Molecular Pathology and Pharmacology Program, Department of Pathology and Bosch Institute University of Sydney Sydney NSW Australia
2. Atta‐ur Rahman School of Applied Biosciences National University of Sciences and Technology Islamabad Pakistan
Funder
Cancer Institute NSW
National Health and Medical Research Council
National Breast Cancer Foundation
Cancer Australia
Cure Cancer Australia Foundation
Publisher
Wiley
Subject
Pharmacology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bph.14985
Reference65 articles.
1. Signaling regulation of genomic and nongenomic functions of estrogen receptors
2. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors
3. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
4. THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes
5. Molecular mechanisms and mode of tamoxifen resistance in breast cancer
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A comparison of in vitro studies between cobalt(III) and copper(II) complexes with thiosemicarbazone ligands to treat triple negative breast cancer;Inorganica Chimica Acta;2024-03
2. Inhibition of autophagy initiation: A novel strategy for oral squamous cell carcinomas;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-02
3. Favipiravir, an antiviral drug, in combination with tamoxifen exerts synergistic effect in tamoxifen-resistant breast cancer cells via hTERT inhibition;Scientific Reports;2024-01-22
4. Differential transmetallation of complexes of the anti-cancer thiosemicarbazone, Dp4e4mT: effects on anti-proliferative efficacy, redox activity, oxy-myoglobin and oxy-hemoglobin oxidation;Chemical Science;2024
5. RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer;Redox Biology;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3